Anti-Obesity Prescription Drugs-EMEA Market Status and Trend Report 2013-2023
Report Summary
Anti-Obesity Prescription Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Anti-Obesity Prescription Drugs industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Anti-Obesity Prescription Drugs 2013-2017, and development forecast 2018-2023
Main market players of Anti-Obesity Prescription Drugs in EMEA, with company and product introduction, position in the Anti-Obesity Prescription Drugs market
Market status and development trend of Anti-Obesity Prescription Drugs by types and applications
Cost and profit status of Anti-Obesity Prescription Drugs, and marketing status
Market growth drivers and challenges
The report segments the EMEA Anti-Obesity Prescription Drugs market as:
EMEA Anti-Obesity Prescription Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA Anti-Obesity Prescription Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Bupropion and Naltrexone
Orlistat
Lorcaserin
Phentermine and Topiramate
Liraglutide
EMEA Anti-Obesity Prescription Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospitals Pharmacies
Retail Pharmacies
E-commerce
EMEA Anti-Obesity Prescription Drugs Market: Players Segment Analysis (Company and Product introduction, Anti-Obesity Prescription Drugs Sales Volume, Revenue, Price and Gross Margin):
VIVUS
Orexigen Therapeutics
Novo Nordisk
F Hoffmann La Roche
Arena Pharmaceuticals
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Anti-Obesity Prescription Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Anti-Obesity Prescription Drugs industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Anti-Obesity Prescription Drugs 2013-2017, and development forecast 2018-2023
Main market players of Anti-Obesity Prescription Drugs in EMEA, with company and product introduction, position in the Anti-Obesity Prescription Drugs market
Market status and development trend of Anti-Obesity Prescription Drugs by types and applications
Cost and profit status of Anti-Obesity Prescription Drugs, and marketing status
Market growth drivers and challenges
The report segments the EMEA Anti-Obesity Prescription Drugs market as:
EMEA Anti-Obesity Prescription Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA Anti-Obesity Prescription Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Bupropion and Naltrexone
Orlistat
Lorcaserin
Phentermine and Topiramate
Liraglutide
EMEA Anti-Obesity Prescription Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospitals Pharmacies
Retail Pharmacies
E-commerce
EMEA Anti-Obesity Prescription Drugs Market: Players Segment Analysis (Company and Product introduction, Anti-Obesity Prescription Drugs Sales Volume, Revenue, Price and Gross Margin):
VIVUS
Orexigen Therapeutics
Novo Nordisk
F Hoffmann La Roche
Arena Pharmaceuticals
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF ANTI-OBESITY PRESCRIPTION DRUGS
1.1 Definition of Anti-Obesity Prescription Drugs in This Report
1.2 Commercial Types of Anti-Obesity Prescription Drugs
1.2.1 Bupropion and Naltrexone
1.2.2 Orlistat
1.2.3 Lorcaserin
1.2.4 Phentermine and Topiramate
1.2.5 Liraglutide
1.3 Downstream Application of Anti-Obesity Prescription Drugs
1.3.1 Hospitals Pharmacies
1.3.2 Retail Pharmacies
1.3.3 E-commerce
1.4 Development History of Anti-Obesity Prescription Drugs
1.5 Market Status and Trend of Anti-Obesity Prescription Drugs 2013-2023
1.5.1 EMEA Anti-Obesity Prescription Drugs Market Status and Trend 2013-2023
1.5.2 Regional Anti-Obesity Prescription Drugs Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Anti-Obesity Prescription Drugs in EMEA 2013-2017
2.2 Consumption Market of Anti-Obesity Prescription Drugs in EMEA by Regions
2.2.1 Consumption Volume of Anti-Obesity Prescription Drugs in EMEA by Regions
2.2.2 Revenue of Anti-Obesity Prescription Drugs in EMEA by Regions
2.3 Market Analysis of Anti-Obesity Prescription Drugs in EMEA by Regions
2.3.1 Market Analysis of Anti-Obesity Prescription Drugs in Europe 2013-2017
2.3.2 Market Analysis of Anti-Obesity Prescription Drugs in Middle East 2013-2017
2.3.3 Market Analysis of Anti-Obesity Prescription Drugs in Africa 2013-2017
2.4 Market Development Forecast of Anti-Obesity Prescription Drugs in EMEA 2018-2023
2.4.1 Market Development Forecast of Anti-Obesity Prescription Drugs in EMEA 2018-2023
2.4.2 Market Development Forecast of Anti-Obesity Prescription Drugs by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Anti-Obesity Prescription Drugs in EMEA by Types
3.1.2 Revenue of Anti-Obesity Prescription Drugs in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Anti-Obesity Prescription Drugs in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Anti-Obesity Prescription Drugs in EMEA by Downstream Industry
4.2 Demand Volume of Anti-Obesity Prescription Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of Anti-Obesity Prescription Drugs by Downstream Industry in Europe
4.2.2 Demand Volume of Anti-Obesity Prescription Drugs by Downstream Industry in Middle East
4.2.3 Demand Volume of Anti-Obesity Prescription Drugs by Downstream Industry in Africa
4.3 Market Forecast of Anti-Obesity Prescription Drugs in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ANTI-OBESITY PRESCRIPTION DRUGS
5.1 EMEA Economy Situation and Trend Overview
5.2 Anti-Obesity Prescription Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 ANTI-OBESITY PRESCRIPTION DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Anti-Obesity Prescription Drugs in EMEA by Major Players
6.2 Revenue of Anti-Obesity Prescription Drugs in EMEA by Major Players
6.3 Basic Information of Anti-Obesity Prescription Drugs by Major Players
6.3.1 Headquarters Location and Established Time of Anti-Obesity Prescription Drugs Major Players
6.3.2 Employees and Revenue Level of Anti-Obesity Prescription Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 ANTI-OBESITY PRESCRIPTION DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 VIVUS
7.1.1 Company profile
7.1.2 Representative Anti-Obesity Prescription Drugs Product
7.1.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of VIVUS
7.2 Orexigen Therapeutics
7.2.1 Company profile
7.2.2 Representative Anti-Obesity Prescription Drugs Product
7.2.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of Orexigen Therapeutics
7.3 Novo Nordisk
7.3.1 Company profile
7.3.2 Representative Anti-Obesity Prescription Drugs Product
7.3.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of Novo Nordisk
7.4 F Hoffmann La Roche
7.4.1 Company profile
7.4.2 Representative Anti-Obesity Prescription Drugs Product
7.4.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of F Hoffmann La Roche
7.5 Arena Pharmaceuticals
7.5.1 Company profile
7.5.2 Representative Anti-Obesity Prescription Drugs Product
7.5.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of Arena Pharmaceuticals
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTI-OBESITY PRESCRIPTION DRUGS
8.1 Industry Chain of Anti-Obesity Prescription Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ANTI-OBESITY PRESCRIPTION DRUGS
9.1 Cost Structure Analysis of Anti-Obesity Prescription Drugs
9.2 Raw Materials Cost Analysis of Anti-Obesity Prescription Drugs
9.3 Labor Cost Analysis of Anti-Obesity Prescription Drugs
9.4 Manufacturing Expenses Analysis of Anti-Obesity Prescription Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF ANTI-OBESITY PRESCRIPTION DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Anti-Obesity Prescription Drugs in This Report
1.2 Commercial Types of Anti-Obesity Prescription Drugs
1.2.1 Bupropion and Naltrexone
1.2.2 Orlistat
1.2.3 Lorcaserin
1.2.4 Phentermine and Topiramate
1.2.5 Liraglutide
1.3 Downstream Application of Anti-Obesity Prescription Drugs
1.3.1 Hospitals Pharmacies
1.3.2 Retail Pharmacies
1.3.3 E-commerce
1.4 Development History of Anti-Obesity Prescription Drugs
1.5 Market Status and Trend of Anti-Obesity Prescription Drugs 2013-2023
1.5.1 EMEA Anti-Obesity Prescription Drugs Market Status and Trend 2013-2023
1.5.2 Regional Anti-Obesity Prescription Drugs Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Anti-Obesity Prescription Drugs in EMEA 2013-2017
2.2 Consumption Market of Anti-Obesity Prescription Drugs in EMEA by Regions
2.2.1 Consumption Volume of Anti-Obesity Prescription Drugs in EMEA by Regions
2.2.2 Revenue of Anti-Obesity Prescription Drugs in EMEA by Regions
2.3 Market Analysis of Anti-Obesity Prescription Drugs in EMEA by Regions
2.3.1 Market Analysis of Anti-Obesity Prescription Drugs in Europe 2013-2017
2.3.2 Market Analysis of Anti-Obesity Prescription Drugs in Middle East 2013-2017
2.3.3 Market Analysis of Anti-Obesity Prescription Drugs in Africa 2013-2017
2.4 Market Development Forecast of Anti-Obesity Prescription Drugs in EMEA 2018-2023
2.4.1 Market Development Forecast of Anti-Obesity Prescription Drugs in EMEA 2018-2023
2.4.2 Market Development Forecast of Anti-Obesity Prescription Drugs by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Anti-Obesity Prescription Drugs in EMEA by Types
3.1.2 Revenue of Anti-Obesity Prescription Drugs in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Anti-Obesity Prescription Drugs in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Anti-Obesity Prescription Drugs in EMEA by Downstream Industry
4.2 Demand Volume of Anti-Obesity Prescription Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of Anti-Obesity Prescription Drugs by Downstream Industry in Europe
4.2.2 Demand Volume of Anti-Obesity Prescription Drugs by Downstream Industry in Middle East
4.2.3 Demand Volume of Anti-Obesity Prescription Drugs by Downstream Industry in Africa
4.3 Market Forecast of Anti-Obesity Prescription Drugs in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ANTI-OBESITY PRESCRIPTION DRUGS
5.1 EMEA Economy Situation and Trend Overview
5.2 Anti-Obesity Prescription Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 ANTI-OBESITY PRESCRIPTION DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Anti-Obesity Prescription Drugs in EMEA by Major Players
6.2 Revenue of Anti-Obesity Prescription Drugs in EMEA by Major Players
6.3 Basic Information of Anti-Obesity Prescription Drugs by Major Players
6.3.1 Headquarters Location and Established Time of Anti-Obesity Prescription Drugs Major Players
6.3.2 Employees and Revenue Level of Anti-Obesity Prescription Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 ANTI-OBESITY PRESCRIPTION DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 VIVUS
7.1.1 Company profile
7.1.2 Representative Anti-Obesity Prescription Drugs Product
7.1.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of VIVUS
7.2 Orexigen Therapeutics
7.2.1 Company profile
7.2.2 Representative Anti-Obesity Prescription Drugs Product
7.2.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of Orexigen Therapeutics
7.3 Novo Nordisk
7.3.1 Company profile
7.3.2 Representative Anti-Obesity Prescription Drugs Product
7.3.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of Novo Nordisk
7.4 F Hoffmann La Roche
7.4.1 Company profile
7.4.2 Representative Anti-Obesity Prescription Drugs Product
7.4.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of F Hoffmann La Roche
7.5 Arena Pharmaceuticals
7.5.1 Company profile
7.5.2 Representative Anti-Obesity Prescription Drugs Product
7.5.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of Arena Pharmaceuticals
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTI-OBESITY PRESCRIPTION DRUGS
8.1 Industry Chain of Anti-Obesity Prescription Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ANTI-OBESITY PRESCRIPTION DRUGS
9.1 Cost Structure Analysis of Anti-Obesity Prescription Drugs
9.2 Raw Materials Cost Analysis of Anti-Obesity Prescription Drugs
9.3 Labor Cost Analysis of Anti-Obesity Prescription Drugs
9.4 Manufacturing Expenses Analysis of Anti-Obesity Prescription Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF ANTI-OBESITY PRESCRIPTION DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
